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Background: Primary tumors of the heart represent an exceedingly rare entity in cardiac surgery and literature
regarding management and outcome is rare. The aim of this study was to translate 15 years of experience in both
multimodal diagnosis and surgical treatment of one of the largest collective of patients in literature into a detailed
analysis of patient prognosis, mean survival and best treatment approach.
Methods and results: All patients who underwent open-heart surgery at the Hospital of the Medical University of
Vienna for primary cardiac tumor excision between 1999 and 2014 were analyzed retrospectively. Mean follow-up
was 76.8 months. Descriptive statistical measurements were applied.
113 patients were identified, 71 (62.8%) female and 42 (37.2%) male patients with a mean age of 57.9 ± 16.8 years.
90.3% (n = 102) masses were benign, 9.7% (n = 11) were malignant. Complete resection was possible for 99% and
for 18.2% of benign and malignant masses, respectively. 2.9% of benign tumors and 45.5% of malignant tumors
relapsed. The 30-day mortality was 1.8% (n = 2). Mean survival was 187.2 ± 2.7 months and 26.2 ± 9.8 months for
benign and malignant pathologies, respectively. Sarcoma patients who underwent adjuvant combination-chemotherapy
or adjuvant mono-chemotherapy and radiation had a statistically significant survival advantage of 41.5 months.
Conclusion: Primary cardiac tumors remain challenging in the clinical setting. A multimodality treatment approach
especially for sarcoma patients prolongs mean survival and should be regarded as the standard of care.
Keywords: Primary cardiac tumorsBackground
Cardiac tumors, both benign and malignant represent
extremely rare diseases and literature on both manage-
ment and outcome is quite limited. Based upon the data
of 22 large autopsy series reported by McAllister et al.,
the frequency of primary cardiac tumors is approximately
0.02%, corresponding to 200 tumors in 1 million autopsies
[1,2]. Malignant tumors metastatic to the heart outnum-
ber primary malignant cardiac tumors by at least a 30-to-
1 ratio in the majority of autopsy series [3]. The reported
incidence of primary cardiac tumors among the general
population has varied between 0.001% and 0.03% in most
studies with cardiac tumors representing only 0.3% of all
open-heart surgeries [4].* Correspondence: andreas.habertheuer@meduniwien.ac.at
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unless otherwise stated.To our knowledge, the first reports on intracavitary mass
formation of the heart are to be traced back to Belgium in
1685 when Zollicoffer wrote “de polypo cordis”. Bahnson
and Newman [5] performed the first successful open surgi-
cal excision of a primary cardiac tumor using the inflow
obstruction technique in 1952 and only 2 years later
Crafoord et al. reported the first successful atrial myxoma
excision using a heart lung bypass [6].
Unless obstructing intracardial flow or interfering with
the valvular [7] and conduction system respectively, car-
diac neoplasms do have the potential to remain clinically
silent until they reach an advanced stage, thereby limiting
therapeutic options especially for those with malignant
transformations [8]. The majority of primary cardiac tu-
mors are benign with more than 80% being myxomas in
various locations and dyspnea being the most common
reason for initial clinical consultation [9]. Malignant car-
diac tumors are mainly comprised of various subsets of
sarcomas with primary cardiac lymphomas forming only antral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,






Age 58.9 ± 16.4 48.8 ± 18.7 0.059
Female gender 66 (64.7) 5 (45.5) 0.209
Urgent intervention 22 (21.6) 10 (90.9) <0.01
Coronary artery disease 8 (7.8) 0 (0.0) 0.335
Valvular heart disease 12 (11.8) 0 (0.0) 0.229
Congenital heart disease 0 (0.0) 1 (9.1) 0.742
Thromboembolic disease 3 (2.9) 0 (0.0) 0.564
Data presented as mean ± standard deviation, n (%) or mean (range).
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tients suffering from malignant transformations is usually
more severe.
The overall objective of the present study was an in-
depth characterization of both benign and malignant pri-
mary cardiac tumors, their frequency as well as age and
gender distribution. 15 years of combined experience in
both diagnosis and multimodal treatment of one of the
largest collective of patients in the scientific literature
were translated into a detailed analysis of patient progno-
sis, mean survival and risk of tumor relapse matched to
the corresponding neoplastic etiology using descriptive
statistical measurements.
Methods
The Medical University of Vienna Medical Record system
and the patient database of the Department of Cardiac
Surgery were retrospectively reviewed to identify patients
with primary cardiac neoplasias. A 15-year period between
1999 through 2014 was analyzed. Approval to conduct
this study was obtained by the Institutional Review Board
of the Medical University of Vienna and patient consent
was waived. The medical records of all patients with pri-
mary heart tumors were reviewed and details regarding
presentation, diagnosis, treatment, and follow-up were ob-
tained. Pathology reports were used to definitely evaluate
both dignity and etiology. Patients with tumors metastatic
to the heart and those in whom a primary cardiac origin
was in doubt were excluded. 2 patients with suspected pri-
mary benign cardiac tumors were subsequently excluded
from the study as their tumors proved to be echinococcal
cysts.
Furthermore, a telephone follow-up was performed for
every patient. Detailed information was requested from
local healthcare providers if necessary. Survival data
were completed with the nationwide statistical database
(‘Statistics Austria’), in which every death is recorded.
The follow-up time was calculated either to death or to
the last verified contact with the living patient. Further-
more, tumor-related events were assessed in the medical
records and through the telephone follow-up. Median
follow-up was 76.8 months (0–180 months).
Treatment consisted of open or minimally invasive
heart surgery for treatment of benign tumors and open-
heart surgery followed by adjuvant therapy for malignant
tumors. Multiple groups of different adjuvant regimens
could be identified. Adjuvant therapy for sarcoma pa-
tients consisted of either combination chemotherapy (6
courses of ifosfamide (1500 mg/m2, days 1–4), dacarbazine
(200 mg/m2, days 1–4) and doxorubicin (25 mg/m2, days
1–2) administered in 14-day intervals and granulocyte-
colony stimulating factor (30 × 106 IU/day, s.c.) on days
5–13) or 6 courses of mono-chemotherapy (doxorubicin)
and radiation, or 6 courses of mono-chemotherapy alone(doxorubicin or herceptin), or radiation alone. One sar-
coma patient did not receive any adjuvant therapy. Radi-
ation dose was age, gender and seize adjusted and ranged
from a total dose of 15 Gy to 60 Gy. Adjuvant therapy for
our patient suffering from a non-Hodgkin lymphoma (dif-
fuse large B-cell lymphoma) consisted of 6 courses of ri-
tuximab, cyclophosphamide, doxorubicin, vincristine and
prednisone (R-CHOP).Statistical analysis
Continuous data are presented as means ± standard de-
viation; skewed data are presented as median and inter-
quartile range. The Kolmogorov–Smirnov test was used
to check for distribution before any additional analysis
was conducted. Categorical data are presented as per-
centage. Differences between groups were compared
using Pearson’s Chi square test for categorical variables
and Student’s T test for continuous variables. Long-term
survival of groups was evaluated and compared using
the Kaplan Meier Survival plot and the log-rank test, re-
spectively. The number of patients at risk was assessed
using life tables. All reported P values are 2-sided and
are considered statistically significant and highly statisti-
cally significant if below 0,05 and below 0.01, respect-
ively. All statistical analyses were performed using SPSS
21.0 (IBM, Armonk, NY, USA).Results
Patient population
The baseline characteristics of patients are depicted in
Table 1. A total of 113 patients underwent surgery for
primary cardiac tumor excision within the study period.
Taking all tumor etiologies into account women suffering
from a cardiac tumor were statistically significant older
(p = 0.02) than their male counterparts at the time of clin-
ical presentation (61.6 ± 14.5 years vs. 51.6 ± 18.7 years).
Analysis for age distribution revealed two peaks at 50 years
and 65 years, respectively. Women had the highest risk of
cardiac tumor formation at 55 and 65 years and men had
the highest risk at 50 and 65 years, respectively.
Habertheuer et al. Journal of Cardiothoracic Surgery  (2015) 10:56 Page 3 of 8Patient presentation
The picture of patients with benign cardiac tumors was
distinct from that of malignant transformation. Com-
mon findings included symptoms of congestive heart fail-
ure (CHF) such as dyspnea (27.5%, n = 28) and central
thromboembolism (8.8%, n = 9), including basilar artery
thromboembolism. It was not uncommon for some pa-
tients to have undergone medical treatment for CHF be-
fore the diagnosis of a cardiac tumor as its underlying
etiology was made. 26.5% (n = 27) of benign masses were
incidental findings during medical evaluations performed
for other reasons (70.4%, n = 19 were actually evaluated
for other cardiac interventions). Only 8 patients with be-
nign masses (7.8%) were truly asymptomatic. Of note, one
patient presented with paroxysmal symptoms of catechol-
amine excess and was found to have a hormone secreting
left atrial paraganglioma linked to a succinate dehydrogen-
ase mutation.
The clinical presentation of patients with an underlying
malignant disease was more severe with 27.7% reportingTable 2 Characteristics of primary benign cardiac tumors
Histology and location No. of patient
Benign 102 (90.3%)
Myxoma 78 (76.5%)
Left atrium 68 (66.6%)
Right atrium 8 (7.8%)
Information not available 2 (2.0%)
Lipomatous hypertrophy 1 (1.0%)
right atrial roof and superior caval vein
True lipoma 1 (1.0%)
right atrial septum, obstructing right atrium
Glomangioma 1 (1.0%)
extracardial, between left atrium and pulmonary artery
Hemangioma 2 (2.0%)
left atrium, anterior mitral valve leaflet 1 (1.0%)
right intralatrial septum 1 (1.0%)
Fibroelastoma 13 (12.7%)
pulmonary valve 1 (1.0%)
aortic valve leaflets 6 (5.9%)
mitral valve leaflets 2 (2.0%)
papillary muscle 2 (2.0%)
apex, occluding the left ventricle* 1 (1.0%)
left ventricular outflow tract (LVOT) 1 (1.0%)
Hamartoma 2 (2.0%)
right atrium, completely obstructing 1 (1.0%)
right ventricle, completely obstructing 1 (1.0%)
hereditary paraganglioma (left atrium)** 1 (0.9%)
Data presented as mean ± standard deviation, n (%) or mean (range).
*Patient underwent successful heart transplantation 4 months later.
**The tumor was hormone secreting with pheochromocytoma-like symptoms. On gensyncope as initial disease presentation and 18.2% present-
ing with cardiac arrest and under mechanical resuscita-
tion. Of note, one patient developed an obstructive left
atrial pleomorphic sarcoma 8 years upon heart trans-
plantation in his cardiac allograft. He died within 2 weeks
after the onset of initial symptoms including dyspnea
due to cardiac arrest. Our non-Hodgkin patient initially
presented with palpitations and arrhythmias, however no
structural abnormalities could be detected on echocar-
diography. Within a period of only two weeks she de-
veloped progressive dyspnea, facial edema and facial
erythema due to almost completely obstructive masses
filling the right atrium and right ventricle (superior vena
cava syndrome) [2].
Tumor characteristics
Tumor characteristics are summarized in Tables 2 and 3,
respectively. The majority of cases (90.3%) were benign
transformations. Myxomas of the left atrium (76.5%) and
fibroelastomas (12.7%) of various locations were largelys (% of benign) Tumor relapse Mean survival (months)
3 187.2 ± 2.7






0 68.5 ± 48.4
0
etic evaluation patient was found to have a succinate dehydrogenase mutation.
Table 3 Characteristics of primary malignant cardiac tumors
Histology and location No. of patients
(% of malignant)
Tumor relapse Distant metastasis Mean survival (months)
Malignant 11 (9.7%) 5 9 26.2 ± 9.8
Sarcoma (all), subtypes 10 (91.0%), subtypes: 5 8 21.1 ± 10.7
Angiosarcoma 3 (27.3%) 2 3 25.3 ± 17.6
right atrium
Intima sarcoma*** 1 (9.1%) 0 1 1.0 ± 0.0
left atrium and anterior mitral valve leaflet, obstructive
Spindle cell sarcoma 1 (9.1%) 1 0 7.0 ± 0.0
right atrium and SVC, completely obstructive
Synovial sarcoma 1 (9.1%) 1 1 64.00 ± 0.0
right atrium/ventricle, obstructing SVC/IVC
Pleomorphic sarcoma**** 1 (9.1%) 0 1 0.0 ± 0.0
left atrium, completely obstructive
Myxofibrosarcoma 2 (18.2%) 0 1 7.0 ± 0.0
left atrium
Myeloid sarcoma 1 (9.1%) 1 1
right atrium, obstructing superior and inferior caval vein
NHL (DLCBL)****** 1 (9.1%) 0 1
right atrium and right ventricle, obstructive
Data presented as mean ± standard deviation, n (%) or mean (range). SVC, superior vana cava; IVC, inferior vena cava.
***Patient underwent cardial autotransplantation.
****Patient had a heart transplantation 8 years ealier. Obstructing sarcoma formation in the left atrium of the heart allograft.
*****One Patient (0.9%) with left atrial myxoma had a tumor relapse as Myxofibrosarcoma 3 months upon surgery.
******NHL indicates Non Hodgkin Lymphoma of the Diffuse Large B-Cell Lymphpma type.
Table 4 Postoperative parameters
Parameter Benign Malignant P value
Early mortality (30d) 1 (1.0) 1 (9.1) 0.053
Tumor related 1 (1.0) 1 (9.1) 0.053
Late mortality (>30d) 1 (1.0) 7 (63.3) <0.01
Tumor related 1 (1.0) 7 (63.3) <0.01
Mean survival (months) 187.2 ± 2.7 26.2 ± 9.8 <0.01
PM dependency 7 (6.9) 2 (18.2) 1.88
Tumor relapse 3 (2.9) 5 (45.5) <0.01
Data presented as mean ± standard deviation, n (%) or mean (range).
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more heterogenous with a high affinity for aortic and
mitral valve leaflets. In general, myxomas were large
obtructive masses measuring up to a couple of centime-
ters while fibroelastomas appeared as small vegetation-
like lesions on valvular leaflets and closely resembled
infectious or thrombotic valvular vegetations on echo-
cardiography. Both left sided myxomas and fibroelas-
tomas had a tendency for central nervous system and
peripheral embolization (11.5% vs. 15.4%). Malignant car-
diac tumors were mainly comprised of various subsets of
sarcomas (90.9%) with primary cardiac lymphomas forming
only a small fraction. Non-Hodgkin lymphomas specific-
ally diffuse large B-cell lymphomas accounted for less than
10%. The most common sarcoma subtype found in our
study was a highly malignant angiosarcoma (n = 3).
Complete tumor excision was possible for 99% versus
18.2% of benign and malignant tumors, respectively.
Tumor relapse and distant metastasis formation
Myxomas appeared to be the only benign masses with a
tendency to recur (2.9%, n = 3). Of note, one myxoma re-
lapsed as a myxofibrosarcoma and presented with indo-
lent fever as the sole symptom highlighting the fact that
those myxoma-myxofibrosarcoma transformations areseldom but do occur with a frequency of about 1.3%. Des-
pite multimodality treatment of malignant tumors with
surgical excision and chemotherapy there was a high rate
of both tumor recurrence and distant metastasis develop-
ment. 45.5% (n = 5) relapsed (p < 0.01) and 72.7% (n = 8)
developed distant metastasis within the follow-up period.
Mortality
Postoperative parameters are depicted in Table 4. The
30-day mortality of all causes was only 1.8% (2 of 113)
despite the aggressive nature especially of sarcomas and
the critical conditions in which patients with large
obstructing masses were presenting, highlighting the
Habertheuer et al. Journal of Cardiothoracic Surgery  (2015) 10:56 Page 5 of 8importance of our center as one of most experienced in
Europe.
The mean survival of patients with an underlying benign
tumor was 187.2 ± 2.7 months compared to a mean sur-
vival of 26.2 ± 9.8 months in patients with a malignant
tumor (Figures 1 and 2A). This finding was statistically
significant by log rank (p < 0.01). When the study end-
point was reached, 98.0% of patients with benign masses
were still alive compared to only 27.3% with malignant
masses. The degree of technically feasible tumor resection
had a significant effect on mean patient survival following
surgery. The mean survival of patients in whom a
complete resection was possible was 45.7 ± 16.4 months
compared to only 9.3 ± 4.2 months for patients in whom
the tumor could not be excised in-toto (p < 0.05 by log
rank). Despite the fact that there was a female predomin-
ance regarding benign cardiac tumors, women had a sta-
tistically insignificant survival advantage of 10 months
(188.0 ± 2.9 months versus 179.9 ± 5.1 months, p = 0.680,
Figure 2B). The exact opposite applied to patients with
an underlying malignant pathology where women had
a statistically insignificant survival disadvantage (16,0 ±
5.1 months versus 22.5 ± 12.5 months, p = 0.469, Figure 2C).
Among the sarcoma group, myeloid sarcomas had the
best prognosis (patient alive at study endpoint) followed
by synovial sarcomas (mean survival of 64.00 ± 0.0 months),
angiosarcomas (25.3 ± 17.6 months), spindle cell sarcomas
and myxofibrosarcomas (both 7.0 ± 0.0 months) and pleo-
morphic sarcomas (0.0 ± 0.0 months). This finding was sta-
tistically significant by log rank test (p < 0.05). Thus, the
histologic sarcoma subtype appeared to have a major affect
on the mean patient survival.Figure 1 Kaplan Meier showing mean survival of all patients with benIn contrast to other authors [14] adjuvant therapy was
found to have a favorable effect on mean patient survival.
We compared the outcomes of various sarcoma adjuvant
regimens consisting of either combination chemotherapy
or 6 courses of doxorubicin and radiation, or mono-
chemotherapy or radiation alone. Patients who under-
went adjuvant combination chemotherapy or doxorubicin
and radiation had a mean survival of 45.7 ± 16.4 months
compared to 4.2 ± 1.4 months in patients who were
treated with either radiation alone (median survival was
4 months) or mono-chemotherapy (median survival was
5 months) or who did not receive any adjuvant therapy.
Statistical significance was reached by log rank (P <
0.05, Figure 3).
Discussion
Taken together our results confirm previous reports in
literature regarding the low incidence of primary cardiac
neoplasias and the 9:1 distribution of benign tumors
compared to malignant tumors. Primary cardiac tumors
remain a rare entity and few surgeons worldwide have
extensive experience in managing them. Secondary car-
diac tumors are 20 to 40 times more common than primary
tumors. The majority of cardiac tumors are metastatic,
with the most common primary tumors being lymph-
omas, leukemias, malignant melanomas, lung and breast
cancers [8,15,16].
The total number of primary cardiac tumors seen at
our institution in 15 years was 113. These are thus ex-
ceedingly rare diagnoses, even in a tertiary center such
as ours. Patients with a malignant mass are 8.6 years
younger (mean 50.1 ± 19.1 years). Women diagnosedign cardiac masses. Mean survival = 187.2 ± 2.7 months.
Figure 2 (A) Mean survival for dignity matched groups (187.2 ± 2.7 months vs. 26.2 ± 9.8 months for benign versus malignant
pathologies, p < 0.01). (B) Mean survival for gender matched groups with benign pathologies (188.0 ± 2.9 months versus 179.9 ± 5.1 months
for female versus male gender). (C) Mean survival for gender matched groups with malignant pathologies (16.0 ± 5.1 months versus 22.5 ±
12.5 months for female versus male gender).
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counterparts (61.6 ± 14.5 years vs. 51.6 ± 18.7 years).
There is a 2-peaked age distribution with women having
the highest risk of cardiac tumor formation between at
55 and 65 years of age and men having the highest risk
at 50 and 65 years, respectively. In contrast to benign
cardiac tumors with a female predominance of 1.7:1, ma-
lignant tumors appear to be equally distributed between
females and males. Benign cardiac tumors do have a pre-
dilection for left sided cardiac structures with myxomas
sharing their most common origin from left atrial struc-
tures [9] and fibroelastomas having their most common
origin at mitral valve leaflets or aortic valve leaflets. In
contrast, malignant cardiac tumors have a predilection
for the right side of the heart.
Both benign and malignant cases can be operatively
managed with excellent results and low early postoperativemortality (30d). However, there is a significant difference
in favor of benign tumors on midterm results and a differ-
ence in favor of adjunctive therapy on malignant patients
and there appears to be some improvement in the current
age of advancements in surgery and medical therapy,
prolonging mean survival of patients with malignant car-
diac tumors. There appears to be some recent advances in
our center, mildely prolonging mean patient survival. The
mean survival as reported in prior studies ranged from
6 months [10,17] to 18 months [8,13]. In the current series
of patients in our center, the mean survival was 26 months,
probably owing to our surgical expertise and the prompt
multimodality treatment approach of combined early
chemotherapy and radiation. Yet, the long-term survival
of patients with malignant cardiac tumors remains poor
and by far lacks behind the mean survival of 187 months
(15.5 years) of patients with benign etiologies.
Figure 3 Survival in comparison to adjuvant treatment regimen matched population. Patients who were treated with adjuvant combination
chemotherapy or doxorubicine and radiation had a statistically significant survival advantage (mean survival 45.7 ± 16.4 months) compared to patients
who were treated with either radiation alone (4 months) or mono-chemotherapy (5 months) or who did not receive any adjuvant therapy. P < 0.05
by log rank.
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both surgery and postoperative adjuvant therapy for
these cancers remains unclear. Some earlier studies have
demonstrated a better survival for patients who under-
went a complete resection compared with patients who
did not while others failed to reach statistical signifi-
cance [12]. In the current study patients with a complete
resection had a median survival of 45.7 ± 16.4 months
compared to only 9.3 ± 4.2 months in those in whom a
complete resection was not technically feasible. There-
fore, a complete resection should always be the mainstay
of surgical treatment. Regarding adjuvant tumor therapy
Llombart-Cussac et al. in their retrospective review of 15
patients undergoing adjuvant chemotherapy after surgery
found that this approach failed to modify the natural
course of the disease [8,14]. In the present study 10 pa-
tients underwent adjuvant therapy consisting of either
combination chemotherapy, or mono-chemotherapy with
radiation or mono-chemotherapy or radiation alone. Pa-
tients who underwent adjuvant combination chemother-
apy or combined doxorubicin mono-chemotherapy and
radiation had a statistically significant survival advantage
(45.7 ± 16.4 months compared to 4.2 ± 1.4 months, p <
0.05), however, a larger collective of patients would be
needed to derive firm conclusion. Based on our results op-
timal patient management consists of early and total
surgical tumor excision followed by combination adjuvant
chemotherapy or adjuvant mono-chemotherapy andradiation. This approach is highly recommended and
should be regarded as the standard of care.
Patients with malignant neoplasias cannot be consid-
ered for heart transplantation as solid organ transplanta-
tions necessitate postoperative immunosuppression. This
would favor secondary metastatic disease.
In conclusion, especially malignant cardiac tumors re-
quire a multimodality treatment approach. Complete tumor
resection and adjuvant therapy should be attempted when-
ever feasible and are to be regarded as the gold standard of
care.Abbreviations
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